Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Diabetes Obesity and Cholesterol Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with diabetes with clinical feature of Xanthelasma will show increased Atherosclerosis.
Objectives:
Primary
To correlate xanthelasma and its severity to pulse wave velocity and atherosclerosis as see in carotid doppler.
Secondary
To correlate xanthelasma to liver fat and fibrosis.
Methodology:
T2DM patient will be recruited from endocrine OPD
Clinical History and Examination:
a. General Physical Examination: Height, weight, waist circumference, hip circumference, BMI, Blood Pressure, Hand grip. Xanthelasma.
Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits
Assessment of sub-clinical atherosclerosis: Pulse wave velocity and carotid Doppler will be done
T2DM is a major public health problem in Asian Indians. Asian Indians develop T2DM at a younger age, and progresses faster than in other ethnic groups. As a result, many diabetes complications are more prevalent and in more advanced stages in Asian countries than in other regions. Asian Indians have one of the highest incidence rates of pre-diabetes and T2DM among all major ethnic groups, and the conversion from pre-diabetes to T2DM occurs more rapidly in this population. According to the Indian Council of Medical Research- India diabetes study (57 117 individuals), the prevalence of prediabetes in all 15 states was 7·3%.
Xanthelasma palpebrarum (XP) are yellow plaques that occur most commonly near the inner canthus of the eyelid and are often associated with atherosclerosis, dyslipidaemia, and coronary artery disease. About 50% of patients who develop xanthelasma have lipid disorder. It is commonly seen in patients with: Type II hyperlipidaemia that includes type IIa, also known as familial hypercholesterolemia, and type IIb, which is commonly referred to as familial combined hyperlipidaemia Type IV hyperlipidaemia, which is also known as familial hypertriglyceridemia: - Diabetes mellitus; Hypothyroidism; Those with low levels of HDL; Fatty diet; Excess alcohol intake; Weight gain.
A significant number of cases of xanthelasma palpebrarum are combined with smoking, central obesity, hypertension, diabetes mellitus, and dyslipidemia which are the major risk factors for CAD. Efforts should be made to rule out the same in high-risk xanthelasma subjects.
Patients with type 2 diabetes mellitus (T2DM) have a high cardiovascular risk even at young age. There is a need to assess this increased risk and identify atherosclerosis early so that appropriate measures for risk reduction can be taken. The Investigators aimed to study carotid-femoral pulse wave velocity (Cf-PWV), a non-invasive indicator of atherosclerosis, in patients with diabetes below 50 years of age and its correlation with markers of obesity and other cardiovascular risk factors.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| With Xanthelasma | T2DM with Xanthelasma |
| |
| Without Xanthelasma | T2DM without Xanthelasma |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clinical Examination | Other | T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma. |
|
| Measure | Description | Time Frame |
|---|---|---|
| To determine correlation of Xanthelasma with Pulse wave velocity, Carotid Doppler scores and Fibrosis | Patient with T2DM and Xanthelasma have a high risk of atherosclerosis. | 12 month |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patient with T2DM visiting Fortis CDOC Hospital will be enrolled in 2 groups cases and controls.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anoop Misra, MD | Contact | 01149101222 | anoopmisra@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Anoop Misra, MD | Fortis CDOC Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fortis CDOC Hospital | Recruiting | Delhi | 110048 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012149 | Restraint, Physical |
| ID | Term |
|---|---|
| D032763 | Behavior Control |
| D013812 | Therapeutics |
| D007103 | Immobilization |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided